Reducing the financial and time toxicities associated with multiple myeloma treatment

Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, discusses the financial and time toxicities associated with multiple myeloma (MM) treatment. Financial toxicity refers to the negative impact on a patient's well-being due to treatment costs, while time toxicity involves unnecessary time spent on healthcare interactions, particularly for patients in remission. Current research is identifying which patients are most affected by financial toxicity, with future efforts focused on mitigation strategies. To reduce time toxicity, less frequent dosing is being explored for drugs like carfilzomib, teclistamab, and the quadruplet regimen Isa-KRd (isatuximab, carfilzomib, lenalidomide, and dexamethasone). This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.